BioCentury | Mar 26, 2019
Financial News

NGM could get $975M valuation in NASDAQ IPO

After setting its NASDAQ IPO terms on Monday, NGM would be valued at $975 million if it prices the offering at the midpoint of its proposed range. The valuation includes a concurrent private placement of...
BioCentury | Jan 18, 2019
Company News

Five Prime cuts headcount by 20% recorded a nine-month operating loss of $105.9 million. Bemarituzumab is a humanized mAb against fibroblast growth factor (FGF) receptor 2 b isoform (FGFR2b)...
BioCentury | Jan 4, 2019
Company News

Merck licenses NASH, diabetes compound from NGM

Merck & Co. Inc. (NYSE:MRK) exercised an option to license exclusive, worldwide rights to MK-3655 (formerly NGM313) from NGM Biopharmaceuticals Inc. (South San Francisco, Calif.). MK-3655, a mAb agonist of the klotho β (KLB)/fibroblast growth...
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
BioCentury | Oct 5, 2018
Financial News

New IPO filings include NGM, Arog, Gamida

Three biotechs filed late Sept. 28 to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
BioCentury | Jun 27, 2016
Clinical News

NGM313: Phase I started

NGM began a double-blind, placebo-controlled, Australian Phase I trial to evaluate single and multiple ascending doses of NGM313 in about 183 healthy overweight or obese volunteers. NGM is developing NGM313 for conditions that include Type...
Items per page:
1 - 6 of 6